A method of treating, reducing, or alleviating a medical condition in a patient is disclosed herein. The method includes administering to a patient in need thereof a biocompatible drug comprising one or more antiviral medications together with one or more cell pathway inhibitors dissolved in a non-toxic semifluorinated alkane, the patient having one or more respiratory tract inflammatory diseases, the one or more cell pathway inhibitors blocking an inflammatory response of inflamed tissue without inhibiting an immune response of the patient, and the semifluorinated alkane evaporating quickly upon administration to the patient so as to leave the biocompatible drug at a desired treatment location. The administration of the biocompatible drug to the patient treats the one or more respiratory tract inflammatory diseases, reduces the symptoms associated with the one or more respiratory tract inflammatory diseases, and/or alleviates one or more respiratory tract inflammatory diseases.

Methods for preventing and/or treating ocular diseases such as dry age-related macular degeneration, and/or improving or maintaining a retinal function, include administering non-invasive photobiomodulation light therapy in the context of a prior PBM treatment, on the basis of a patient pre-treatment characteristic. In some embodiments, methods comprise administering PBM therapy to subjects prior to onset of, or in early stages of, dry age-related macular degeneration.

A method of mitigating the development of myopia, includes measuring elasticity of collagen of an eye; identifying an eye for which the elasticity measured is above a preselected threshold; selectively applying a collagen cross-linking reagent proximate collagen of a sclera of a posterior pole portion of the eye for which the elasticity measured is above the preselected threshold; and irradiating at least the posterior pole portion of the eye with radiation of an appropriate wavelength to initiate covalent bonding and cross-linking of the collagen for which the elasticity measured is above the preselected threshold.

A dual blade device and method useable for performing an ab interno procedure within a human eye to remove a strip of trabecular meshwork tissue.

A micro-device for corneal cross-linking treatment includes a body including an outer portion and an inner portion. The outer portion is disposed about a periphery of the inner portion. The inner portion is shaped such that, when the body is positioned against a surface of an eye, the outer portion contacts the surface of the eye and the inner portion defines a chamber over a cornea of the eye. The micro-device includes an illumination system including a micro-optical element coupled to the body. The micro-optical element is configured to direct photoactivating light to the cornea of the eye when the body is positioned against the surface of the eye. The photoactivating light generates cross-linking activity with a cross-linking agent applied to the cornea.

The present invention is broadly directed to an artificial lighting system 30 for emitting artificial light in an indoor environment for controlling myopia in humans. The artificial lighting system 30 generally comprises: 1. one or more luminaires such as 34a to 34d designed to directly generate and emit artificial light without filters which substantially simulates the effect of sunlight and is of a predetermined wavelength emission spectrum (a) higher in its proportion of wavelengths at or around 480 nm relatively to neighbouring wavelengths, and (b) lower in its proportion of high energy visible light; 2. an electronic control module 36 operatively coupled to the luminaires such as 34a to control their emission of the artificial light.

A method of corneal implantation with cross-linking is disclosed herein. In one or more embodiments, the method includes the steps of: (i) forming a flap in a cornea of an eye so as to expose a stromal tissue of the cornea underlying the flap; (ii) pivoting the flap so as to expose the stromal tissue of the cornea underlying the flap; (iii) inserting an implant under the flap so as to overlie the stromal tissue of the cornea; (iv) applying laser energy and/or microwaves to the implant in the eye so as to modify the refractive power of the implant; (v) applying a cross-linking solution that includes a photosensitizer to the implant; (vi) covering the implant with the flap; and (vii) irradiating the implant so as to activate cross-linkers in the implant, and thereby cross-link the implant and the stromal tissue of the cornea surrounding the implant.

Provided are multi-wavelength phototherapy devices, systems and methods for the treatment of a disorder or disease, including multi-wavelength low level light therapy (PBM), in particular to multi-wavelength PBM and other phototherapy systems and methods for improving functionality in and/or restoring functionality to a cell and/or tissue through the coordinated and targeted delivery to the cell or tissue of two or more doses of light having distinct wavelengths, wherein the two or more doses of light, when delivered in a coordinated fashion, can stimulate the activity of two or more light sensitive factors that, when activated, provide and/or enhance a desired target cell functionality. Ophthalmic phototherapy devices, systems, and treatment methods to expose an eye to selected multi-wavelengths of light to promote the healing of damaged or diseased eye tissue. The devices include a housing having an interior; an eyepiece disposed on the housing and configured and arranged for placement of an eye of the patient adjacent the eyepiece; a first light source producing a first light beam having a first therapeutic wavelength and disposed within the housing; a second light source producing a second light beam having a second therapeutic wavelength and disposed within the housing, where the second therapeutic wavelength differs from the first therapeutic wavelength by at least 25 nm.

A corneal cross-linking system includes a light source configured to emit a photoactivating light. The system includes a spatial light modulator configured to receive the photoactivating light from the light source and provide a pixelated illumination. The spatial light modulator defines a maximum area for the pixelated illumination. The system includes a controller configured to cause the spatial light modulator to project a first pixelated illumination onto the cornea to photoactivate a cross-linking agent applied to a treatment area. The first pixelated illumination has an area that is smaller than the maximum area defined by the spatial light modulator. The controller is configured to determine movement of the cornea. In response to the movement, the controller controls the spatial light modulator to project a second pixelated illumination to the treatment area based on a translation and/or transformation of the first pixelated illumination to continue photoactivating the cross-linking agent.

Certain embodiments describe an endoilluminator having a tube that includes an interior compartment between a proximal end and a distal end of the tube, wherein the distal end of the tube is configured to be inserted into an eye. The endoilluminator also includes a handpiece coupled to a light source and the proximal end of the tube, wherein the endoilluminator is configured to filter an incident component of light transmitted by the light source and emit a polarized component of the transmitted light through the distal end of the tube.